SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the companys cell encapsulation technology and its benefits for treating chronic diseases such as diabetes. The Companys technology involves encapsulating insulin-producing cells that respond to changes in glucose levels into the Cell-in-a-Box platform. As a result, the treatment would potentially eliminate the need for diabetes patients to continually test their glucose levels and inject insulin.

The Goldman report cited the completed animal study wherein SG Austria successfully treateddiabetesin an established, recognized animal model utilizing liveencapsulatedcells. In the study, the introduced cells responded to elevated blood sugar levels by producing insulin, thereby alleviating thesymptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.

The report stated, This data, as well as previously published results, demonstrate it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells. This should pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would present a more natural means of providing insulin to patients, mimicking the body's own insulin production and thereby maintaining healthy blood glucose levels.

The long term effects of diabetes include kidney failure, blindness, heart disease, amputations, and stroke. The World Health Organization (WHO) reports346 million people in the world have diabetes and 4 million deaths occur globally each year. In fact, more than $378 billion is spent annually on diabetes treatment with the number expected to rise to $490 billion by 2030.

The report concluded that, Although it is early in the development process, the prospects on the diabetes front could be huge for the Company. Goldman set a current value of Nuvilex at $0.30 per share with a six month price target of $0.50 per share based on the cell encapsulation technology and the favorable clinical and pre-clinical trial results across multiple biotechnology fields.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, added, We are hopeful that through use of our cell encapsulation platform patients will no longer have to rely on daily insulin injections. The ultimate objective, if future trials prove effective, will be for patients to receive encapsulated live cell treatments intermittently, possibly as infrequently as every 3 to 6 months or longer, dramatically changing their lives.

Investors are recommended to study the Goldman Research Report for a detailed review and valuation methodology regarding Nuvilex.

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of biotechnology and clinically useful, therapeutic live-cell encapsulation products and services for the research and medical communities. Through substantial effort, Nuvilex and SG Austria are rapidly moving toward our initial phase of funding acquisition and initial agreement completion. One of our first planned offerings is to include cancer treatments using the companys industry-leading live-cell encapsulation technology.

Original post:
Nuvilex’s Diabetes Treatment Utilizing Implanted Encapsulated, Insulin-Producing Cells Potentially Eliminates Need for ...